

March 7, 2016

The Honorable Gregory Smith, Chairperson  
Senate Committee on Corrections and Juvenile Justice  
Statehouse, Room 441-E  
Topeka, Kansas 66612

Dear Senator Smith:

SUBJECT: Fiscal Note for SB 483 by Senate Committee on Federal and State Affairs

In accordance with KSA 75-3715a, the following fiscal note concerning SB 483 is respectfully submitted to your committee.

SB 483 would make a number of changes to the Uniform Controlled Substances Act to include the following:

1. Change the name of the drug *psilocin* to *psilocyn*;
2. Add *acetyl fentanyl* to Schedule I of the controlled substances lists;
3. Add *2-N-ethanamine* and *1-alkoxy-1-oxoalkan-2-yl* to the chemical compound of *indazole-3-carboxamides*;
4. Delete the term "synthetic" from the description of *dronabinol*; and
5. Add *eluxadoline* and its salts, isomers, and salts of isomers to Schedule IV of the controlled substances lists.

The State Board of Pharmacy indicates SB 483 would have no fiscal effect on its operation, but could have an effect on other state agencies and local units of government since making drugs illegal has the potential to result in more arrests. The Kansas Sentencing Commission indicates any increase in prison beds, prison admissions, and journal entries cannot be determined at this time. Any fiscal effect resulting from the enactment of SB 483 is not included in *The FY 2017 Governor's Budget Report*.

Sincerely,



Shawn Sullivan,  
Director of the Budget

cc: Alexandra Blasi, Board of Pharmacy  
Scott Schultz, Sentencing Commission